- Home
- ALLO vs IHRT Comparison
ALLO vs IHRT Comparison
Compare ALLO & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | IHRT |
|---|---|---|
| Founded | 2017 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Broadcasting |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 589.5M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALLO | IHRT |
|---|---|---|
| Price | $2.02 | $2.73 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 15 | 2 |
| Target Price | ★ $8.35 | $4.25 |
| AVG Volume (30 Days) | ★ 5.2M | 614.0K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.09 | ★ 54.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,864,991,000.00 |
| Revenue This Year | N/A | $9.96 |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.27 |
| 52 Week Low | $1.04 | $2.05 |
| 52 Week High | $4.46 | $6.56 |
Technical Indicators
Market Signals| Indicator | ALLO | IHRT |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 35.75 |
| Support Level | $1.87 | $2.55 |
| Resistance Level | $2.25 | $3.93 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 38.71 | 13.99 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About IHRT iHeartMedia Inc.
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.